Ott_a_203342 8355..8365
Diyu Chen,Hao Wu,Bin He,Yue Lu,W. Wu,Hua Liu,Xiaode Feng,Jianzhong Chen,Jianzhong Wu
2019-01-01
Abstract:1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People’s Republic of China; 2Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310003, Zhejiang, People’s Republic of China; 3Key Laboratory of Organ Transplantation, Hangzhou 310003, Zhejiang, People’s Republic of China; 4Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang, People’s Republic of China; 5Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang, People’s Republic of China Background: Cholangiocarcinoma (CCA) is a subtype of highly malignant hepatic tumor, which has low 5-year survival rate and poor clinical outcome. Only a few patients can be detected early and accepted with the surgery. Most of CCA patients are diagnosed in